Biogen (BIIB) tops earnings expectations, reveals workforce reduction
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall as megacap tech drags; Iran developments watched
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
GE, General Motors, Verizon rise premarket; Goldman Sachs, Dow fall
July 25, 2023 7:50 AM EDTInvesting.com -- U.S. futures edged higher Tuesday, as investors digest a deluge of corporate earnings ahead of a key Federal Reserve meeting.
Here are some of the biggest premarket U.S. stock movers today:
General Motors (NYSE: GM) stock rose 2% after the auto giant lifted its full-year... More
Biogen announces job cuts, turns focus to Alzheimer's drug launch
July 25, 2023 7:04 AM EDTBy Manas Mishra and Mariam Sunny
(Reuters) -Biogen Inc said on Tuesday it expects to slash about 1,000 jobs, or 11% of its workforce, in a fresh round of cost-cutting as it looks to the launch of a new Alzheimer's drug to help it return to growth.
The company said its costs are elevated compared to rivals and that it would focus on higher-growth products such as the recently approved Alzheimer's drug Leqembi, which it sells with partner Eisai.
"We had very prosperous times in the more recent history of the company. And we have seen a... More
Biogen (BIIB) Tops Q2 EPS by 24c, Offers Guidance
July 25, 2023 7:02 AM EDTBiogen (NASDAQ: BIIB) reported Q2 EPS of $4.02, $0.24 better than the analyst estimate of $3.78. Revenue for the quarter came in at $2.46 billion versus the consensus estimate of $2.37 billion.
GUIDANCE:
Biogen sees FY2023 EPS of $15.00-$16.00, versus the consensus of $15.43.
Total revenue... MoreBiogen (BIIB) PT Lowered to $335 at UBS
July 24, 2023 9:22 AM EDTUBS analyst Colin Bristow lowered the price target on Biogen (NASDAQ: BIIB) to $335.00 (from $346.00) while maintaining a Buy rating.... More
